Beijing-based Biotech Company BioInnovatis Signs Antibody Evaluation Agreement with Merck

BeijingApril 29, 2022PR Newswire -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") announced that it has signed an antibody drug molecule evaluation agreement with Merck, which includes an option. Biocytogen grants Merck the exclusive right to evaluate its proprietary antibody molecules targeting at least three novel targets. After completing the evaluation, Merck has the option to obtain global rights to the selected antibody molecules for the development of therapeutic products for any use.

According to the agreement, Merck will select at least three drug targets from Biocytogen's "Thousand Mouse Antibody" project, and Biocytogen will provide Merck with its proprietary RenMice platform targeting the selected targets.^TMAntibody molecules generated by the platform. After Merck completes the feasibility testing of the antibody molecules and exercises its option, it will be responsible for further research, development, and commercialization of the selected products. In the future, this agreement may also be expanded to include other targets agreed upon by both parties.

Dr. Yuelei Shen, President and CEO of Biocytogen, stated: "We thank Merck for recognizing our proprietary technology platform and antibody discovery capabilities. We believe that the differentiated candidate drug molecules generated by our innovative models and antibody discovery platform can rapidly advance the development of antibody-based innovative therapies. Our approach is based on RenMice."^TMThe Thousand Mouse and Antibody Project of the platform aims to discover numerous promising antibody molecules for more than 1,000 potential drug targets. We welcome global partners to join us in unlocking the full potential of this platform.